EMA's CHMP Recommends Aumseqa for Non-Small Cell Lung Cancer in November Verdict

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Aumseqa (aumolertinib), a third-generation EGFR inhibitor, for the treatment of non-small cell lung cancer. This recommendation is part of the CHMP's November session verdict, signaling an acceleration in the pace of new medicine recommendations and an increasing demand for post-approval evidence generation from sponsors.